Latest Insider Transactions at Lineage Cell Therapeutics, Inc. (LCTX)
This section provides a real-time view of insider transactions for Lineage Cell Therapeutics, Inc. (LCTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Lineage Cell Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Lineage Cell Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 24
2024
|
Brian M Culley President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+6.07%
|
$10,000
$1.05 P/Share
|
|
Feb 11
2024
|
George A. Samuel Iii General Counsel/Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
2,490
-25.74%
|
$2,490
$1.08 P/Share
|
|
Feb 11
2024
|
George A. Samuel Iii General Counsel/Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
6,076
+38.58%
|
-
|
|
Feb 11
2024
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,806
-8.12%
|
$12,806
$1.08 P/Share
|
|
Feb 11
2024
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,249
+16.54%
|
-
|
|
Feb 08
2024
|
Don M Bailey Director |
BUY
Open market or private purchase
|
Indirect |
96,155
+37.71%
|
$96,155
$1.04 P/Share
|
|
Feb 06
2024
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Feb 06
2024
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Direct |
6,730,770
+13.91%
|
$6,730,770
$1.04 P/Share
|
|
Dec 29
2023
|
Anula Jayasuriya Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$10,000
$1.09 P/Share
|
|
Feb 11
2023
|
George A. Samuel Iii General Counsel/Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
2,478
-40.78%
|
$2,478
$1.35 P/Share
|
|
Feb 11
2023
|
George A. Samuel Iii General Counsel/Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
6,076
+50.0%
|
-
|
|
Feb 11
2023
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,744
-9.16%
|
$12,744
$1.35 P/Share
|
|
Feb 11
2023
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,249
+18.34%
|
-
|
|
Feb 11
2023
|
Gary S. Hogge SVP,Clinical & Medical Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
5,310
-40.78%
|
$5,310
$1.35 P/Share
|
|
Feb 11
2023
|
Gary S. Hogge SVP,Clinical & Medical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
13,020
+50.0%
|
-
|
|
Jun 30
2022
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,343
-4.72%
|
$5,343
$1.58 P/Share
|
|
Jun 30
2022
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,450
+12.01%
|
-
|
|
Mar 31
2022
|
Brian M Culley President and CEO |
BUY
Open market or private purchase
|
Direct |
6,400
+6.14%
|
$6,400
$1.53 P/Share
|
|
Mar 31
2022
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,343
-5.52%
|
$5,343
$1.54 P/Share
|
|
Mar 31
2022
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,450
+13.77%
|
-
|
|
Mar 28
2022
|
Dipti Amin Director |
BUY
Open market or private purchase
|
Direct |
35,000
+50.0%
|
$35,000
$1.63 P/Share
|
|
Mar 25
2022
|
Brian M Culley President and CEO |
BUY
Open market or private purchase
|
Direct |
5,250
+6.07%
|
$5,250
$1.38 P/Share
|
|
Mar 25
2022
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Mar 25
2022
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Direct |
470,000
+1.33%
|
$470,000
$1.44 P/Share
|
|
Mar 24
2022
|
Michael H. Mulroy Director |
BUY
Open market or private purchase
|
Direct |
7,000
+2.64%
|
$7,000
$1.4 P/Share
|
|
Mar 24
2022
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Mar 24
2022
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Direct |
200,000
+0.58%
|
$200,000
$1.42 P/Share
|
|
Mar 23
2022
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Mar 23
2022
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Direct |
260,106
+0.75%
|
$260,106
$1.37 P/Share
|
|
Dec 31
2021
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,343
-6.57%
|
$10,686
$2.45 P/Share
|
|
Dec 31
2021
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,450
+15.96%
|
-
|
|
Dec 29
2021
|
Gary S. Hogge SVP,Clinical & Medical Affairs |
SELL
Open market or private sale
|
Direct |
37,695
-62.27%
|
$75,390
$2.47 P/Share
|
|
Dec 29
2021
|
Gary S. Hogge SVP,Clinical & Medical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
9,250
+19.7%
|
$0
$0.69 P/Share
|
|
Dec 28
2021
|
Gary S. Hogge SVP,Clinical & Medical Affairs |
SELL
Open market or private sale
|
Direct |
501,588
-94.63%
|
$1,003,176
$2.45 P/Share
|
|
Dec 28
2021
|
Gary S. Hogge SVP,Clinical & Medical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
501,588
+31.32%
|
$501,588
$1.31 P/Share
|
|
Sep 30
2021
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,343
-7.5%
|
$10,686
$2.52 P/Share
|
|
Sep 30
2021
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,450
+17.82%
|
-
|
|
Jun 30
2021
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,343
-8.74%
|
$10,686
$2.85 P/Share
|
|
Jun 30
2021
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,450
+20.17%
|
$30,900
$2.85 P/Share
|
|
Jun 29
2021
|
Angus C. Russell Director |
SELL
Open market or private sale
|
Direct |
4,720
-5.12%
|
$9,440
$2.97 P/Share
|
|
Jun 29
2021
|
Angus C. Russell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,720
+21.14%
|
$49,440
$2.2 P/Share
|
|
Jun 29
2021
|
Deborah J Andrews Director |
SELL
Open market or private sale
|
Direct |
19,142
-55.13%
|
$38,284
$2.93 P/Share
|
|
Jun 29
2021
|
Deborah J Andrews Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,720
+41.59%
|
$49,440
$2.2 P/Share
|
|
Jun 28
2021
|
Brian M Culley President and CEO |
SELL
Open market or private sale
|
Direct |
450,000
-90.78%
|
$900,000
$2.87 P/Share
|
|
Jun 28
2021
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+37.7%
|
$0
$0.69 P/Share
|
|
Jun 25
2021
|
Neal C Bradsher Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,720
+22.0%
|
$49,440
$2.2 P/Share
|
|
Jun 22
2021
|
Alfred D Kingsley Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
61,800
+1.12%
|
$123,600
$2.2 P/Share
|
|
Jun 18
2021
|
Michael H. Mulroy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,720
+8.95%
|
$49,440
$2.2 P/Share
|
|
Mar 31
2021
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,343
-2.66%
|
$10,686
$2.35 P/Share
|
|
Mar 31
2021
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,450
+7.14%
|
$30,900
$2.35 P/Share
|